Therefore, although the AF‐FLOW Global Registry lacks internal controls and consists of only 25 patients, it demonstrates that the findings in FLOW‐AF and EVAL FLOW‐AF are robust in a new, broader population and that the benefits of EGF mapping still apply in real‐world settings where physicians use it as a primary or supplemental tool to their standard workflow. Here, EGF is linked to atrial fibrillation.